Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Pet Deal benchmark

<< Previous

Bullboard Posts

Next >>

Comment by biorunon Oct 24, 2022 11:51am

121 Views

Post# 35043835

RE:RE:RE:Pet Deal benchmark

Yes, I am with you on this forhandlaren.

There are 4 majors listed in the September presentation update and Elanco is only one of them.

If Elanco confirmed its a new market to pursue, others will definitely jump on board and there are really no other options here for the other 3 top 10 animal health listed to pursue and compete with Elanco on.

So this could get extremely interesting to say the least.

On verra.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals